Scrip Clinical Trials

ResMed Says GLP-1s Won’t Affect Business As Earnings Beat Expectations

George Underwood — Fri, 01 May 2026 15:21:33 +0000

Analysts had worried that GLP-1 weight-loss drugs might reduce demand for ResMed’s sleep apnea products — but the company revealed data showing that its positive airway pressure products could work in

Robotic Mastectomy Comparable To Open Surgery, But Ergonomics May Shift Surgeon Preference

Phalguni Deswal — Fri, 01 May 2026 15:12:34 +0000

The 27th Annual Meeting of the American Society of Breast Surgeons (ASBrS), held from April 29 to May 3, delivered high-impact studies that collectively signal an era of treatment de-escalation, preci

Summit’s Bet On Early Success For Ivonescimab Falls Flat

Andrew McConaghie — Fri, 01 May 2026 14:17:22 +0000

Summit’s high-stakes development of the dual PD-1xVEGF inhibitor ivonescimab has taken another twist, with an early lung cancer data peek for a Phase III global trial disappointing. The US-based compa

UniQure Targets UK Okay For Huntington’s Gene Therapy After FDA Clashes

Kevin Grogan — Fri, 01 May 2026 13:54:42 +0000

Given all the regulatory hurdles UniQure has encountered in the US for its closely watched gene therapy for Huntington’s disease, it is looking more likely that a first approval could come from across

Scrip M&A Podcast: What Can We Infer From The First Quarter’s Late Deal Flurry

Joseph Haas — Fri, 01 May 2026 13:42:03 +0000

Assessing merger-and-acquisition activity in the biopharmaceutical sector following a first quarter that ended with a rush of larger “bolt-on” transactions, Cooley LLP’s Kevin Cooper and Bill Roegge

Indoco Refocuses With ‘Non-Core’ India And Africa Divestment

Dean Rudge — Fri, 01 May 2026 11:57:44 +0000

Indoco Remedies is divesting its ophthalmic division in India and many African markets through a slump sale to Sunways (India) Private Limited, marking a strategic step to sharpen its focus on “core t

Henlius-Organon Wins EU’s First Perjeta Biosimilar Approval

Urtė Fultinavičiūtė — Fri, 01 May 2026 10:38:56 +0000

The European Commission has granted a marketing authorization for the first and only pertuzumab biosimilar in Europe. Poherdy, which is partnered by Shanghai Henlius Biotech and Organon, was approved

Teva Meets European Ambition On Olanzapine

Dean Rudge — Fri, 01 May 2026 10:30:08 +0000

Much of Teva’s first-quarter earnings call was dominated by chatter about the firm’s same-day announcement that it had agreed a bolt-on addition to its branded neuroscience portfolio in the form of Em

What’s Next? Five Things To Look Out For In May

Dean Rudge — Fri, 01 May 2026 08:46:25 +0000

Bio-Thera/Accord’s Golimumab Faces FDA Action Date Partners Bio-Thera Solutions and Intas’ Accord Healthcare are this month set to hear word in the US regarding their proposed BAT2506 golimumab biosim

Podcast: Carna Health On Closing the Gap in CKD Prevention

Anabel Costa-Ferreira — Fri, 01 May 2026 08:32:55 +0000

Often described as a “hidden epidemic,” chronic kidney disease is asymptomatic in its early stages, leading to late diagnosis and poor outcomes. “I think it’s been a neglected organ, a neglected disea

Chugai Focuses On Innovation Capabilities As Its Logs Solid Q1

Lisa Takagi — Fri, 01 May 2026 07:56:52 +0000

Chugai closed its calendar first quarter with solid growth in both revenue, which rose to JPY321.7bn ($2.06bn; +11.5%), and operating profit, which was up 17.1% to JPY163.3bn. The weak Japanese yen ad

US Consumer Health News Digest: Business, Regulation, Science

Malcolm Spicer — Fri, 01 May 2026 01:15:17 +0000

Farm Bill Goes To Senate The House Agriculture Committee’s farm bill for fiscal years 2027-2031 heads to the Senate without language to postpone a lower limit taking effect in November on all forms of

Alternate Leadership Strategy: Deputy Director Szarama Is Acting US FDA Biologics Center Chief

Derrick Gingery — Fri, 01 May 2026 01:04:33 +0000

A relative newcomer to the US Food and Drug Administration will take over temporarily for outgoing Center for Biologics Evaluation and Research Director Vinay Prasad. A Health and Human Services Depar

US FDA AdComm Says Camizestrant Novel Trial Design Provocative, But Not Paradigm-Shifting

Bridget Silverman — Fri, 01 May 2026 00:55:54 +0000

The novel design of the pivotal SERENA-6 trial overshadowed its new molecular entity subject when the US Food and Drug Administration’s Oncologic Drugs Advisory Committee reviewed AstraZeneca ’s cami

US FDA Panel Backs AstraZeneca’s Truqap In Prostate Cancer Despite Toxicities

Sue Sutter — Fri, 01 May 2026 00:16:12 +0000

The 7.5-month radiographic progression-free survival benefit with AstraZeneca ’s Truqap (capivasertib) will be clinically meaningful to some metastatic hormone-sensitive prostate cancer patients desp

Axoft Raises $55M To Advance Brain-Computer Interface Toward FDA Approval In 2027

Marion Webb — Fri, 01 May 2026 00:14:08 +0000

Axoft landed another significant investment round, which will allow it to expand clinical trials in pursuit of US regulatory clearance for its implantable brain-computer interface designed to help com

CoaChrom Diagnostica GmbH

Fri, 01 May 2026 00:08:32 +0000

https://www.coachrom.com/en/

Elsohly Laboratories,INC

Fri, 01 May 2026 00:08:29 +0000

http://www.elsohly.com

Innovation1 Biotech

Fri, 01 May 2026 00:08:26 +0000

https://i1bio.com/

Akzo Nobel N.V.

Fri, 01 May 2026 00:08:20 +0000

https://www.akzonobel.com/en